Skip to main content

Lung

Protocols

Non-Small Cell Lung Cancer (Adjuvant)

ULUAJATZ

Adjuvant Treatment of Resected Non-Small Cell Lung Cancer using Atezolizumab

LUAJNP

Adjuvant CISplatin and vinorelbine following resection of non-small cell lung cancer


LUAJOSI

Adjuvant Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) with Osimertinib

LUAJPC

Adjuvant CARBOplatin and PACLitaxel following resection of stage I, II and IIIA non-small cell lung cancer

LUAJPP

Adjuvant CISplatin and Pemetrexed Following Resection of Non-Small Cell Lung Cancer

LULADUR

Locally Advanced Non-Small Cell Lung Cancer Using Durvalumab

LULADUR4

Treatment of Locally Advanced Non-Small Cell Lung Cancer Using 4-Weekly Durvalumab

Top

Non-Small Cell Lung Cancer (Advanced)

Targeted Therapy

LUAVAFAT

First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Afatinib

LUAVALE

Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Alectinib

LUAVBRI

First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Brigatinib

LUAVCER

Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Ceritinib

LUAVCRIZ

Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib

LUAVCRIZF

First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib

LUAVCRIZR

First-Line Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib

LUAVENT

First-Line Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Entrectinib

LUAVERL

Second- or Later-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib

LUAVGEFF

First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Gefitinib

LUAVMTNE

Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib After First-Line Chemotherapy

LUAVOSI

Treatment of EGFR T790M Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Osimertinib

LUAVOSIF

First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Osimertinib

LUAVSEL

Treatment of RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Selpercatinib

Immunotherapy

LUAVATZ

Treatment of Advanced Non-Small Cell Lung Cancer Using Atezolizumab

LUAVATZ4

Treatment of Advanced Non-Small Cell Lung Cancer Using 4-Weekly Atezolizumab

LUAVNIV

Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab

LUAVNIV4

Treatment of Advanced Non-Small Cell Lung Cancer Using 4-Weekly Nivolumab

LUAVPCIPNI

First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with PACLitaxel, CARBOplatin, Ipilimumab and Nivolumab

 

LUAVPCPMB

First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with PACLitaxel, CARBOplatin and Pembrolizumab

LUAVPGPMB

First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Platinum, Gemcitabine and Pembrolizumab

LUAVPMB

Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab

LUAVPMB6

Treatment of Advanced Non-Small Cell Lung Cancer Using 6-Weekly Pembrolizumab

LUAVPMBM

Maintenance Therapy of Advanced Non-Small Cell Lung Cancer with Pembrolizumab

LUAVPMBM6

Maintenance Therapy of Advanced Non-Small Cell Lung Cancer with 6-Weekly Pembrolizumab

LUAVPPIPNI

First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab

LUAVPPMBM

Maintenance Therapy of Advanced Non-Squamous Non-Small Cell Lung Cancer with Pemetrexed and Pembrolizumab

LUAVPPPMB

First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed and Pembrolizumab

LUAVPMBF

First-Line Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab

LUAVPMBF6

First-Line Treatment of Advanced Non-Small Cell Lung Cancer Using 6-Weekly Pembrolizumab

Chemotherapy

LUAVDC

First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with CISplatin and DOCEtaxel

LUAVDOC

Second or Later-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with DOCEtaxel

LUAVNP

Treatment for advanced non-small cell lung cancer (NSCLC) with CISplatin and vinorelbine

LUAVPC

First-Line treatment of advanced non-small cell lung cancer (NSCLC) with CARBOplatin and PACLitaxel

LUAVPEM

Second-Line Chemotherapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed

LUAVPG

Treatment of advanced non-small cell lung cancer (NSCLC) with platinum and gemcitabine

LUAVPMTN

Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed

LUAVPP

First-Line Treatment of Advanced Non-Small Cell Lung Cancer With Platinum and Pemetrexed

LUAVVIN

Treatment of advanced non-small cell lung cancer (NSCLC) with vinorelbine in elderly patients

Top

Non-Small Cell Lung Cancer (Combined Modality Therapy)

LULACATRT

Treatment of Locally Advanced Non-Small Cell Lung Cancer using CARBOplatin and PACLitaxel with Radiation Therapy

LULAPE2RT

Treatment of locally advanced non-small cell lung cancer using Alternative Dosing of CISplatin and etoposide with radiation therapy

LULAPERT

Treatment of locally advanced non-small cell lung cancer using CISplatin and etoposide with radiation therapy

Top

Small Cell Lung Cancer (Limited Stage)

LUSCPEPORT

Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral Etoposide with Radiation Therapy

LUSCPERT

Therapy of limited stage small cell lung cancer using CISplatin and etoposide with radiation

Top

Small Cell Lung Cancer (Extensive Stage)

LUSCATPE

Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide

LUSCCAV

Treatment of Extensive Small Cell Lung Cancer (SCLC) with Cyclophosphamide, DOXOrubicin and vinCRIstine (CAV)

LUSCDURPE

Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide

LUSCPE

Therapy of extensive stage small cell lung cancer (SCLC) with CISplatin and etoposide

LUSCPEPO

Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Oral Etoposide

LUSCPI

Second-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Irinotecan With or Without Platinum

LUSCPOE

Palliative therapy of extensive stage small cell lung cancer (SCLC) with oral Etoposide

LUSCTOP

Second line treatment of recurrent small cell lung cancer (SCLC) with topotecan

Top

Malignant Mesothelioma

LUMMIPNI

Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab

LUMMIPNI3

Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab

LUMMPG

Treatment of malignant mesothelioma with platinum and gemcitabine

LUMMPP

Treatment of Malignant Mesothelioma with Platinum and Pemetrexed

LUMMVIN

Treatment of Malignant Mesothelioma with Vinorelbine

Top

Other Thoracic Malignancies

LUNETEV

Treatment of Advanced Neuroendocrine Tumours of Lung Origin (Non-Functional) Using Everolimus

LUOTCAV

Treatment of Thymoma/Thymic Carcinoma with Cyclophosphamide, DOXOrubicin and vinCRIstine (CAV)

LUOTPAC

Treatment of Thymoma with Platinum, DOXOrubicin and Cyclophosphamide

LUOTPE

Treatment of thymoma with CISplatin and etoposide

LUOTPERT

Treatment of thymoma using CISplatin and etoposide with radiation therapy

LUPUPE

Treatment of Cancer of Unknown Primary Involving the Thorax with CISplatin and etoposide

Funding Algorithm

The funding algorithm provides information on what anti-cancer systemic therapy treatments are covered on the BC Cancer Benefit Drug List (formulary). It may not be a complete list of all treatment options that may be available and recommended by the treating physician.

Terms of use

The information contained in these documents is a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's Terms of Use.

Tab Heading
SOURCE: Lung ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2023 Provincial Health Services Authority